Clinical Trial Update: Rapid Analysis and Response Evaluation of Combination Anti-Neoplastic Agents in Rare Tumors (RARE CANCER) Trial: RARE 1 Nilotinib and Paclitaxel [Phase 2]

View source ↗

Summary

Phase 2 trial update for a combination of nilotinib and paclitaxel in rare tumors; recruitment is ongoing.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neoplasms

Drugs mentioned

• PACLITAXEL (PACLITAXEL)
• Tasigna (nilotinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Neoplasms | Phase 2 | Status: RECRUITING